AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca interest-bearing loans and borrowings — non-current ($M) ($M)
Consolidated Statement of Financial Position (Postgres DB)
Latest, Q2 2026
23,683
Period ended Jun 30, 2026
Change on a year earlier
-4.2%
24,714 in Q2 2025
History
32 quarters
Since Q4 2015
Sources
29
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Interest-bearing loans and borrowings — non-current ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 23,683 | -4.2% | Form 6-K (filed 2026-07-27) ↗ |
| Q1 2026 | Mar 31, 2026 | -24,454 | -8.4% | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | 24,715 | -6.8% | Form 20-F (filed 2026-02-24) ↗ |
| Q3 2025 | Sep 30, 2025 | -24,700 | -14.5% | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | 24,714 | -9.2% | Form 6-K (filed 2025-07-29) ↗ |
| Q1 2025 | Mar 31, 2025 | -26,692 | -2.1% | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | 26,506 | +18.5% | Form 20-F (filed 2025-02-18) ↗ |
| Q3 2024 | Sep 30, 2024 | -28,887 | +30.0% | Form 6-K FY2024Q3 Earnings Release ↗ |
| Q2 2024 | Jun 30, 2024 | 27,225 | +11.9% | Form 6-K (filed 2024-07-25) ↗ |
| Q1 2024 | Mar 31, 2024 | -27,259 | +1.3% | Form 6-K FY2024Q1 Earnings Release ↗ |
| Q4 2023 | Dec 31, 2023 | 22,365 | -2.6% | Form 20-F (filed 2024-02-20) ↗ |
| Q3 2023 | Sep 30, 2023 | -22,225 | -3.4% | Form 6-K FY2023Q3 Earnings Release ↗ |
| Q2 2023 | Jun 30, 2023 | 24,329 | -8.1% | Form 6-K (filed 2023-07-28) ↗ |
| Q1 2023 | Mar 31, 2023 | -26,916 | -4.1% | Form 6-K FY2023Q1 Earnings Release ↗ |
| Q4 2022 | Dec 31, 2022 | 22,965 | -18.4% | Form 20-F (filed 2023-02-21) ↗ |
| Q3 2022 | Sep 30, 2022 | -23,013 | -18.4% | Form 6-K FY2022Q3 Earnings Release ↗ |
| Q2 2022 | Jun 30, 2022 | 26,461 | +9.8% | Form 6-K (filed 2022-07-29) ↗ |
| Q1 2022 | Mar 31, 2022 | -28,081 | +61.3% | Form 6-K FY2022Q1 Earnings Release ↗ |
| Q4 2021 | Dec 31, 2021 | 28,134 | +60.7% | Form 20-F (filed 2022-02-22) ↗ |
| Q3 2021 | Sep 30, 2021 | -28,206 | – | Form 6-K FY2021Q3 Earnings Release ↗ |
| Q2 2021 | Jun 30, 2021 | 24,109 | +59.1% | Form 6-K (filed 2021-07-30) ↗ |
| Q1 2021 | Mar 31, 2021 | -17,410 | – | Form 6-K FY2021Q1 Earnings Release ↗ |
| Q4 2020 | Dec 31, 2020 | 17,505 | +11.3% | Form 20-F (filed 2021-02-16) ↗ |
| Q2 2020 | Jun 30, 2020 | 15,150 | -12.7% | Form 6-K/A (filed 2020-07-31) ↗ |
| Q4 2019 | Dec 31, 2019 | 15,730 | -9.4% | Form 20-F (filed 2020-03-03) ↗ |
| Q2 2019 | Jun 30, 2019 | 17,355 | +12.3% | Form 6-K (filed 2019-07-25) ↗ |
| Q4 2018 | Dec 31, 2018 | 17,359 | +11.6% | Form 20-F (filed 2019-03-05) ↗ |
| Q2 2018 | Jun 30, 2018 | 15,452 | -8.0% | Form 6-K (filed 2018-07-26) ↗ |
| Q4 2017 | Dec 31, 2017 | 15,560 | +7.3% | Form 20-F (filed 2018-03-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 16,792 | – | Form 6-K (filed 2018-07-26) ↗ |
| Q4 2016 | Dec 31, 2016 | 14,501 | +2.6% | Form 20-F (filed 2018-03-06) ↗ |
| Q4 2015 | Dec 31, 2015 | 14,137 | – | Form 20-F (filed 2018-03-06) ↗ |
Cite this data
StockData. (2026). AstraZeneca Interest-bearing loans and borrowings — non-current ($M) ($M), quarterly Q4 2015–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/fin_lt_debt
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.